ASPEN PHAR.UN.ADR /1 O.N. (F:LDZU) — Stock Price
ASPEN PHAR.UN.ADR /1 O.N. (F:LDZU) is currently trading at €6.90 EUR, up 4.55% today. Over the past 52 weeks, shares have ranged between €4.26 and €7.35. This page tracks ASPEN PHAR.UN.ADR /1 O.N.'s live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see LDZU stock market capitalisation.
ASPEN PHAR.UN.ADR /1 O.N. (LDZU) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ASPEN PHAR.UN.ADR /1 O.N.'s daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
ASPEN PHAR.UN.ADR /1 O.N. Income Statement — Revenue, Profit & Earnings by Year
ASPEN PHAR.UN.ADR /1 O.N.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | €43.36 Billion | €44.71 Billion | €40.71 Billion | €38.61 Billion |
| Cost of Revenue | €24.23 Billion | €25.25 Billion | €22.30 Billion | €20.30 Billion |
| Gross Profit | €19.13 Billion | €19.45 Billion | €18.41 Billion | €18.31 Billion |
| Research & Development | — | — | — | — |
| SG&A | €5.46 Billion | €5.06 Billion | €4.60 Billion | €4.33 Billion |
| Total Operating Expenses | €34.74 Billion | €34.26 Billion | €32.46 Billion | €29.82 Billion |
| Operating Income | €8.62 Billion | €10.45 Billion | €8.25 Billion | €8.79 Billion |
| EBITDA | — | — | — | — |
| EBIT | — | — | — | — |
| Interest Expense | €1.65 Billion | €2.23 Billion | €1.32 Billion | €765.00 Million |
| Income Before Tax | €-123.00 Million | €5.71 Billion | €6.55 Billion | €8.13 Billion |
| Income Tax Expense | — | — | — | — |
| Net Income | €-1.08 Billion | €4.40 Billion | €5.23 Billion | €6.49 Billion |
ASPEN PHAR.UN.ADR /1 O.N. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ASPEN PHAR.UN.ADR /1 O.N.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | €135.89 Billion | €139.06 Billion | €134.28 Billion | €111.38 Billion |
| Total Current Assets | €38.70 Billion | €44.09 Billion | €44.50 Billion | €34.56 Billion |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | — | — | — | — |
| Net Receivables | €10.65 Billion | €10.30 Billion | €10.09 Billion | €8.24 Billion |
| Inventory | €18.01 Billion | €18.00 Billion | €19.61 Billion | €15.76 Billion |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | €5.20 Billion | €5.70 Billion | €5.60 Billion | €5.01 Billion |
| Total Liabilities | €51.00 Billion | €54.20 Billion | €48.05 Billion | €40.43 Billion |
| Total Current Liabilities | €17.50 Billion | €24.30 Billion | €23.15 Billion | €23.39 Billion |
| Long-term Debt | €31.26 Billion | €24.82 Billion | €21.38 Billion | €10.58 Billion |
| Net Debt | €29.21 Billion | €23.52 Billion | €18.21 Billion | €15.94 Billion |
| Total Stockholder Equity | €84.89 Billion | €84.86 Billion | €86.24 Billion | €70.94 Billion |
| Retained Earnings | €58.09 Billion | €60.76 Billion | €58.13 Billion | €54.34 Billion |
ASPEN PHAR.UN.ADR /1 O.N. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ASPEN PHAR.UN.ADR /1 O.N. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | €5.16 Billion | €6.22 Billion | €5.52 Billion | €5.37 Billion |
| Capital Expenditures | €5.05 Billion | €5.54 Billion | €3.18 Billion | €2.70 Billion |
| Free Cash Flow | €104.00 Million | €690.00 Million | €2.34 Billion | €2.68 Billion |
| Investing Cash Flow | — | — | — | — |
| Financing Cash Flow | — | — | — | — |
| Dividends Paid | €1.60 Billion | €1.52 Billion | €1.46 Billion | €1.20 Billion |
| Stock-Based Compensation | €109.00 Million | €117.00 Million | €135.00 Million | €58.00 Million |
| Depreciation | €2.09 Billion | €1.97 Billion | €1.79 Billion | €1.71 Billion |
| Change in Cash | €-811.00 Million | €-273.00 Million | €2.52 Billion | €-1.46 Billion |
ASPEN PHAR.UN.ADR /1 O.N. Earnings History — EPS Actual vs. Analyst Estimates
Track ASPEN PHAR.UN.ADR /1 O.N.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 02, 2026 | — | — | — |
| Dec 05, 2025 | — | — | — |
| Sep 03, 2025 | — | — | — |
| Mar 03, 2025 | — | — | — |
| Dec 05, 2024 | — | — | — |